Indiana Code
Chapter 24. Central Repository for Controlled Substances Data
25-26-24-18. Program Requirements; Execution of Contracts; Data; Funding

Sec. 18. (a) The INSPECT program must do the following:
(1) Create a data base for information required to be transmitted under section 17 of this chapter in the form required under rules adopted by the board, including search capability for the following:
(A) An ephedrine, pseudoephedrine, or a controlled substance recipient's name.
(B) An ephedrine, pseudoephedrine, or a controlled substance recipient's or recipient representative's identification number.
(C) An ephedrine, pseudoephedrine, or a controlled substance recipient's date of birth.
(D) The national drug code number of ephedrine, pseudoephedrine, or a controlled substance dispensed.
(E) The dates ephedrine, pseudoephedrine, or a controlled substance are dispensed.
(F) The quantities of ephedrine, pseudoephedrine, or controlled substance dispensed.
(G) The number of days of supply dispensed.
(H) A dispenser's United States Drug Enforcement Agency registration number.
(I) A prescriber's United States Drug Enforcement Agency registration number.
(J) Whether a prescription was transmitted to the pharmacist orally or in writing.
(K) An ephedrine, pseudoephedrine, or a controlled substance recipient's method of payment for the ephedrine, pseudoephedrine, or controlled substance dispensed.
To the extent considered appropriate by the board, the data base must be interoperable with other similar registries operated by federal and state governments.
(2) Provide the board with continuing twenty-four (24) hour a day online access to the data base.
(3) Secure the information collected and the data base maintained against access by unauthorized persons.
(b) The board may not execute a contract with a vendor designated by the board to perform any function associated with the administration of the INSPECT program, unless the contract has been approved by the committee.
(c) The INSPECT program may gather prescription data from the Medicaid retrospective and prospective drug utilization review (DUR) program established under IC 12-15-35.
(d) The board may accept and designate grants, public and private financial assistance, and licensure fees to provide funding for the INSPECT program.
As added by P.L.51-2019, SEC.8.